A phase 1 study on PD01A on PD carriers of mutations in the Glucocerebrosidase gene (GBA), was withdrawn in October 2017, before recruiting the first participant (ClinicalTrials.gov ID: NCT02758730). This evidence concerns the gene GBA1 and Parkinson disease.